Do analysts prefer CIGL or BIAF?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Concorde International Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 bioAffinity Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, CIGL or BIAF?

bioAffinity Technologies has lower revenue, but higher earnings than Concorde International Group. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Concorde International Group $12.48M 8.38 -$15.24M N/A N/A bioAffinity Technologies $6.16M 0.51 -$14.91M -$11.77 N/A

Do analysts recommend BIAF or CISO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score bioAffinity Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 CISO Global 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer BIAF or CISO?

In the previous week, bioAffinity Technologies had 3 more articles in the media than CISO Global. MarketBeat recorded 6 mentions for bioAffinity Technologies and 3 mentions for CISO Global. CISO Global's average media sentiment score of 0.63 beat bioAffinity Technologies' score of 0.16 indicating that CISO Global is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment bioAffinity Technologies 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral CISO Global 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer BIAF or BTOC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score bioAffinity Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Armlogi 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer SYRA or BIAF?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Syra Health 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 bioAffinity Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer SYRA or BIAF?

In the previous week, bioAffinity Technologies had 4 more articles in the media than Syra Health. MarketBeat recorded 6 mentions for bioAffinity Technologies and 2 mentions for Syra Health. Syra Health's average media sentiment score of 0.37 beat bioAffinity Technologies' score of 0.16 indicating that Syra Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Syra Health 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral bioAffinity Technologies 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Do analysts prefer PSQH or BIAF?

PSQ currently has a consensus price target of $52.50, indicating a potential upside of 1,476.58%. Given PSQ's stronger consensus rating and higher possible upside, equities research analysts clearly believe PSQ is more favorable than bioAffinity Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PSQ 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 bioAffinity Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is PSQH or BIAF more profitable?

PSQ has a net margin of -143.15% compared to bioAffinity Technologies' net margin of -280.53%. PSQ's return on equity of -217.16% beat bioAffinity Technologies' return on equity. Company Net Margins Return on Equity Return on Assets PSQ -143.15% -217.16% -53.86% bioAffinity Technologies -280.53% -285.75% -143.71%

Does the media favor PSQH or BIAF?

In the previous week, bioAffinity Technologies had 4 more articles in the media than PSQ. MarketBeat recorded 6 mentions for bioAffinity Technologies and 2 mentions for PSQ. PSQ's average media sentiment score of 0.33 beat bioAffinity Technologies' score of 0.16 indicating that PSQ is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PSQ 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral bioAffinity Technologies 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

bioAffinity Technologies (BIAF) Competitors

$0.66 -0.01 (-1.18%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$0.66 0.00 (-0.29%)

As of 07/24/2026 07:34 PM Eastern

Compare

BIAF vs. CIGL, CISO, BTOC, SYRA, and PSQH

Should you buy bioAffinity Technologies stock or one of its competitors? MarketBeat compares bioAffinity Technologies with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with bioAffinity Technologies include Concorde International Group (CIGL), CISO Global (CISO), Armlogi (BTOC), Syra Health (SYRA), and PSQ (PSQH). These companies are all part of the "business services" industry.

How does bioAffinity Technologies compare to Concorde International Group?

Concorde International Group (NASDAQ:CIGL) and bioAffinity Technologies (NASDAQ:BIAF) are both small-cap business services companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, profitability, analyst recommendations, dividends and media sentiment.

bioAffinity Technologies has lower revenue, but higher earnings than Concorde International Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Concorde International Group	$12.48M	8.38	-$15.24M	N/A	N/A
bioAffinity Technologies	$6.16M	0.51	-$14.91M	-$11.77	N/A

In the previous week, bioAffinity Technologies had 1 more articles in the media than Concorde International Group. MarketBeat recorded 6 mentions for bioAffinity Technologies and 5 mentions for Concorde International Group. bioAffinity Technologies' average media sentiment score of 0.16 beat Concorde International Group's score of 0.15 indicating that bioAffinity Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Concorde International Group	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
bioAffinity Technologies	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

1.6% of bioAffinity Technologies shares are owned by institutional investors. 2.7% of bioAffinity Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Concorde International Group has a beta of 2.76, indicating that its share price is 176% more volatile than the broader market. Comparatively, bioAffinity Technologies has a beta of -1.11, indicating that its share price is 211% less volatile than the broader market.

Concorde International Group has a net margin of 0.00% compared to bioAffinity Technologies' net margin of -280.53%. Concorde International Group's return on equity of 0.00% beat bioAffinity Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Concorde International Group	N/A	N/A	N/A
bioAffinity Technologies	-280.53%	-285.75%	-143.71%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Concorde International Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
bioAffinity Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Concorde International Group beats bioAffinity Technologies on 6 of the 11 factors compared between the two stocks.

How does bioAffinity Technologies compare to CISO Global?

bioAffinity Technologies (NASDAQ:BIAF) and CISO Global (NASDAQ:CISO) are both small-cap business services companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, earnings, profitability, media sentiment and institutional ownership.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
bioAffinity Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
CISO Global	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

CISO Global has a net margin of -16.69% compared to bioAffinity Technologies' net margin of -280.53%. CISO Global's return on equity of -32.61% beat bioAffinity Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
bioAffinity Technologies	-280.53%	-285.75%	-143.71%
CISO Global	-16.69%	-32.61%	-17.19%

1.6% of bioAffinity Technologies shares are owned by institutional investors. Comparatively, 40.1% of CISO Global shares are owned by institutional investors. 2.7% of bioAffinity Technologies shares are owned by company insiders. Comparatively, 23.8% of CISO Global shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

CISO Global has higher revenue and earnings than bioAffinity Technologies. CISO Global is trading at a lower price-to-earnings ratio than bioAffinity Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
bioAffinity Technologies	$6.16M	0.51	-$14.91M	-$11.77	N/A
CISO Global	$26.61M	0.44	-$8.07M	-$0.24	N/A

bioAffinity Technologies has a beta of -1.11, meaning that its share price is 211% less volatile than the broader market. Comparatively, CISO Global has a beta of 1.74, meaning that its share price is 74% more volatile than the broader market.

In the previous week, bioAffinity Technologies had 3 more articles in the media than CISO Global. MarketBeat recorded 6 mentions for bioAffinity Technologies and 3 mentions for CISO Global. CISO Global's average media sentiment score of 0.63 beat bioAffinity Technologies' score of 0.16 indicating that CISO Global is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
bioAffinity Technologies	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
CISO Global	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

CISO Global beats bioAffinity Technologies on 10 of the 13 factors compared between the two stocks.

How does bioAffinity Technologies compare to Armlogi?

bioAffinity Technologies (NASDAQ:BIAF) and Armlogi (NASDAQ:BTOC) are both small-cap business services companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, valuation, dividends, earnings and analyst recommendations.

Armlogi has a net margin of -10.70% compared to bioAffinity Technologies' net margin of -280.53%. Armlogi's return on equity of -104.33% beat bioAffinity Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
bioAffinity Technologies	-280.53%	-285.75%	-143.71%
Armlogi	-10.70%	-104.33%	-13.30%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
bioAffinity Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Armlogi	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

bioAffinity Technologies has a beta of -1.11, suggesting that its stock price is 211% less volatile than the broader market. Comparatively, Armlogi has a beta of 2.75, suggesting that its stock price is 175% more volatile than the broader market.

In the previous week, bioAffinity Technologies had 5 more articles in the media than Armlogi. MarketBeat recorded 6 mentions for bioAffinity Technologies and 1 mentions for Armlogi. Armlogi's average media sentiment score of 1.87 beat bioAffinity Technologies' score of 0.16 indicating that Armlogi is being referred to more favorably in the news media.

Company	Overall Sentiment
bioAffinity Technologies	Neutral
Armlogi	Very Positive

1.6% of bioAffinity Technologies shares are held by institutional investors. 2.7% of bioAffinity Technologies shares are held by company insiders. Comparatively, 66.9% of Armlogi shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

bioAffinity Technologies has higher earnings, but lower revenue than Armlogi. Armlogi is trading at a lower price-to-earnings ratio than bioAffinity Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
bioAffinity Technologies	$6.16M	0.51	-$14.91M	-$11.77	N/A
Armlogi	$190.41M	0.06	-$15.35M	-$0.47	N/A

Summary

Armlogi beats bioAffinity Technologies on 8 of the 13 factors compared between the two stocks.

How does bioAffinity Technologies compare to Syra Health?

Syra Health (NASDAQ:SYRA) and bioAffinity Technologies (NASDAQ:BIAF) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, media sentiment, earnings, analyst recommendations and profitability.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Syra Health	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
bioAffinity Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

4.8% of Syra Health shares are held by institutional investors. Comparatively, 1.6% of bioAffinity Technologies shares are held by institutional investors. 36.5% of Syra Health shares are held by company insiders. Comparatively, 2.7% of bioAffinity Technologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Syra Health has a beta of 2.94, suggesting that its stock price is 194% more volatile than the broader market. Comparatively, bioAffinity Technologies has a beta of -1.11, suggesting that its stock price is 211% less volatile than the broader market.

Syra Health has higher revenue and earnings than bioAffinity Technologies. Syra Health is trading at a lower price-to-earnings ratio than bioAffinity Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Syra Health	$7.98M	1.16	-$2.94M	-$0.02	N/A
bioAffinity Technologies	$6.16M	0.51	-$14.91M	-$11.77	N/A

Syra Health has a net margin of -54.90% compared to bioAffinity Technologies' net margin of -280.53%. Syra Health's return on equity of -131.94% beat bioAffinity Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Syra Health	-54.90%	-131.94%	-99.19%
bioAffinity Technologies	-280.53%	-285.75%	-143.71%

In the previous week, bioAffinity Technologies had 4 more articles in the media than Syra Health. MarketBeat recorded 6 mentions for bioAffinity Technologies and 2 mentions for Syra Health. Syra Health's average media sentiment score of 0.37 beat bioAffinity Technologies' score of 0.16 indicating that Syra Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Syra Health	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
bioAffinity Technologies	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Syra Health beats bioAffinity Technologies on 11 of the 14 factors compared between the two stocks.

How does bioAffinity Technologies compare to PSQ?

PSQ (NYSE:PSQH) and bioAffinity Technologies (NASDAQ:BIAF) are both small-cap business services companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings, media sentiment and valuation.

PSQ has a net margin of -143.15% compared to bioAffinity Technologies' net margin of -280.53%. PSQ's return on equity of -217.16% beat bioAffinity Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PSQ	-143.15%	-217.16%	-53.86%
bioAffinity Technologies	-280.53%	-285.75%	-143.71%

In the previous week, bioAffinity Technologies had 4 more articles in the media than PSQ. MarketBeat recorded 6 mentions for bioAffinity Technologies and 2 mentions for PSQ. PSQ's average media sentiment score of 0.33 beat bioAffinity Technologies' score of 0.16 indicating that PSQ is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PSQ	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
bioAffinity Technologies	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

PSQ currently has a consensus price target of $52.50, indicating a potential upside of 1,476.58%. Given PSQ's stronger consensus rating and higher possible upside, equities research analysts clearly believe PSQ is more favorable than bioAffinity Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PSQ	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
bioAffinity Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

PSQ has a beta of 0.44, suggesting that its share price is 56% less volatile than the broader market. Comparatively, bioAffinity Technologies has a beta of -1.11, suggesting that its share price is 211% less volatile than the broader market.

17.3% of PSQ shares are owned by institutional investors. Comparatively, 1.6% of bioAffinity Technologies shares are owned by institutional investors. 12.2% of PSQ shares are owned by insiders. Comparatively, 2.7% of bioAffinity Technologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

bioAffinity Technologies has lower revenue, but higher earnings than PSQ. PSQ is trading at a lower price-to-earnings ratio than bioAffinity Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PSQ	$18.22M	0.59	-$36.61M	-$12.14	N/A
bioAffinity Technologies	$6.16M	0.51	-$14.91M	-$11.77	N/A

Summary

PSQ beats bioAffinity Technologies on 12 of the 16 factors compared between the two stocks.

Get bioAffinity Technologies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BIAF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BIAF vs. The Competition

Export

Metric	bioAffinity Technologies	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.13M	$3.67B	$7.06B	$12.20B
Dividend Yield	N/A	2.19%	2.67%	9.41%
P/E Ratio	-0.06	21.29	27.14	23.63
Price / Sales	0.51	297.82	582.30	111.98
Price / Cash	N/A	153.89	49.81	58.78
Price / Book	0.41	7.88	10.28	6.01
Net Income	-$14.91M	$23.86M	$3.60B	$331.99M
7 Day Performance	-6.22%	-3.82%	-1.27%	-0.63%
1 Month Performance	-20.49%	-4.45%	-1.67%	-3.04%
1 Year Performance	-93.41%	33.01%	18.25%	13.30%

bioAffinity Technologies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BIAF bioAffinity Technologies	0.5892 of 5 stars	$0.66 -1.2%	N/A	-93.4%	$3.13M	$6.16M	N/A	10	News Coverage Analyst Upgrade Short Interest Decrease
CIGL Concorde International Group	N/A	$0.56 -67.1%	N/A	-84.5%	$12.38M	$11.07M	N/A	134	Analyst Forecast Gap Down
CISO CISO Global	0.8783 of 5 stars	$0.27 +6.6%	N/A	-76.1%	$11.64M	$26.61M	N/A	443	News Coverage
BTOC Armlogi	0.7222 of 5 stars	$0.25 -1.2%	N/A	-84.2%	$11.41M	$193.63M	N/A	N/A	Positive News Gap Down High Trading Volume
SYRA Syra Health	N/A	$0.80 +4.6%	N/A	+570.0%	$11.01M	$7.98M	N/A	78	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BIAF) was last updated on 7/26/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

bioAffinity Technologies (BIAF) Competitors

BIAF vs. CIGL, CISO, BTOC, SYRA, and PSQH

How does bioAffinity Technologies compare to Concorde International Group?

Summary

How does bioAffinity Technologies compare to CISO Global?

Summary

How does bioAffinity Technologies compare to Armlogi?

Summary

How does bioAffinity Technologies compare to Syra Health?

Summary

How does bioAffinity Technologies compare to PSQ?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIAF vs. The Competition

bioAffinity Technologies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

bioAffinity Technologies (BIAF) Competitors

BIAF vs. CIGL, CISO, BTOC, SYRA, and PSQH

How does bioAffinity Technologies compare to Concorde International Group?

Which has higher valuation and earnings, CIGL or BIAF?

Does the media favor CIGL or BIAF?

Do institutionals and insiders believe in CIGL or BIAF?

Which has more risk and volatility, CIGL or BIAF?

Is CIGL or BIAF more profitable?

Do analysts prefer CIGL or BIAF?

Summary

How does bioAffinity Technologies compare to CISO Global?

Do analysts recommend BIAF or CISO?

Is BIAF or CISO more profitable?

Do insiders and institutionals hold more shares of BIAF or CISO?

Which has stronger valuation and earnings, BIAF or CISO?

Which has more risk and volatility, BIAF or CISO?

Does the media prefer BIAF or CISO?

Summary

How does bioAffinity Technologies compare to Armlogi?

Is BIAF or BTOC more profitable?

Do analysts prefer BIAF or BTOC?

Which has more risk and volatility, BIAF or BTOC?

Does the media prefer BIAF or BTOC?

Do insiders & institutionals have more ownership in BIAF or BTOC?

Which has better valuation & earnings, BIAF or BTOC?

Summary

How does bioAffinity Technologies compare to Syra Health?

Do analysts prefer SYRA or BIAF?

Do institutionals and insiders have more ownership in SYRA or BIAF?

Which has more risk & volatility, SYRA or BIAF?

Which has higher valuation and earnings, SYRA or BIAF?

Is SYRA or BIAF more profitable?

Does the media prefer SYRA or BIAF?

Summary

How does bioAffinity Technologies compare to PSQ?

Is PSQH or BIAF more profitable?

Does the media favor PSQH or BIAF?

Do analysts prefer PSQH or BIAF?

Which has more risk and volatility, PSQH or BIAF?

Do insiders & institutionals believe in PSQH or BIAF?

Which has stronger earnings and valuation, PSQH or BIAF?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIAF vs. The Competition

bioAffinity Technologies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools